Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Novocure Announced A Late Breaking Abstract That Reviews The Results Of An Exploratory Subgroup Analysis Of The Phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 Trial Has Been Selected At The European Society On Gynecological Oncology 2024 Congress

Author: Benzinga Newsdesk | March 11, 2024 07:15am

Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone

Posted In: NVCR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist